Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program

Quell Therapeutics, Ltd. announces that AstraZeneca has selected a candidate to progress in the Type 1 Diabetes Treg cell therapy program.